Orphan Drugs Warrant Flexibility On Clinical Pharmacology Data, FDA Panel Says
Executive Summary
FDA should use its regulatory flexibility to require fewer pre-approval clinical pharmacology studies, with increased emphasis on post-marketing studies and mandatory registries, to speed development of orphan drugs, the agency’s Advisory Committee for Pharmaceutical Science and Clinical Pharmacology said.
You may also be interested in...
Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes
Rare disease advocates are wondering whether it may be time to strengthen the Orphan Drug Act and at least one organization is researching potential improvements that could be made to the pathway.
Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes
Rare disease advocates are wondering whether it may be time to strengthen the Orphan Drug Act and at least one organization is researching potential improvements that could be made to the pathway.
PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue
FDA and industry have reached agreement on four issues in the Prescription Drug User Fee Act reauthorization, including adjustments to risk-benefit policy and creation of a meta-analysis team.